Who we are

GC Aesthetics are international market leaders with over 40 years of industry experience. Our goal is to empower and support individuals on their body-transformation journey, with innovation and continuous improvement as key drivers of our product portfolio.


Corporate profile

We are a vibrant, international, company in tune with the needs of our customers. Our aim is to educate and empower individuals to feel in charge of changing the way they feel about themselves.

With decades of market presence (*using Nagor and Eurosilicone) and experience in the breast implants industry we have developed:

Management Team

Carlos Reis Pinto

Chief Executive Officer (CEO)

Length of service: December 2016 – present day Role and responsibilities: Coordinating the efficiency, profitability and growth of GCA. Career highlights: 20 years’ experience of driving operational excellence including 11 years with GE Healthcare and 6 years as COO of Cerba Healthcare in the lab industry. Performance enabler.

David FitzGerald

Chief Finance & Administrative Officer (CFO)

Length of Service: September 2018 – Present Day Roles & Responsibilities: Leading the global Finance & admin, IT and strategy team to drive and support profitable growth for GCA Career highlights: 30 years’ experience delivering results in business transformation and business building in many sectors in including food & beverage, software, pharma & medical device distribution and sports nutrition. Problem solver.

Ron Cosmas

Chief Commercial Officer (CCO)

With over 20 years of commercial and executive leadership experience building brand, clinical and regulatory awareness within the aesthetic and reconstructive arena.  He will lead the GC Aesthetics North American PMA effort, while cultivating brand awareness, developing a key opinion leader network and establishing clinical research sites within the United States.
Prior to joining GCA, he led the Sales & Marketing efforts at Keller Medical(Keller Funnel), recently acquired by Allergan.  His previous experience included 8 years as a founding member of the initial Sientra team and 8 years with Allergan Breast Aesthetics

Fara Naomi Macias

Head of Marketing

8 year career in Medical Aesthetics, Beauty and Healthcare Industry, developing brands, products and business units, sustaining and growing revenue and market share within highly competitive markets.

Her previous experience includes the launch of GCA brands in Mexico, achieving market leadership in only 2 years as Sales and Marketing Director. Delivers from strategy to execution offering a complete value to doctors and patients.

Chris Brotherston, PhD

Head Of Medical Affairs

Coming from a background in applied research Chris has held various regulatory, quality, clinical & technical leadership roles in the last 20 years and has experience managing across borders and delivering various solutions in global markets across aesthetics, anaesthetic and scar management sectors.

David Beot

Chief Information Officer (CIO)

With over 15 years as a successful IT leader for different companies, David joined GCA in 2019 leading the group IT strategy. He has strong experience of IT transformation and management and delivering projects and services are his main goal. David holds an engineering degree and a masters in production.

Monique Marcellin

Head of Supply Chain

Over 15 years of Experience improving supply chain organizations in various well-known companies as Galderma, Bioderma, oenobiol or Rhodia. Great experience on leveraging supply chain as a key enabler for customers value creation.

Monique hold a master’s degree Industrial and Logistic Management.

Stephen Barsanti

UK Manufacturing Site

Stephen Barsanti joined us 20 years ago and has led the UK Operations for the last four years. Having held various roles from engineering, research and development and operations management.  Stephen has a 1st class Honours degree in mechanical engineering and a Ph. D in heart valve research.

Fabien Rolland

France Manufacturing Site

After 16 years in Healthcare business within General Electric group, Fabien joined GCA in 2018.  He has engineering, manufacturing, operations, international sales and business development experiences and hold a biomechanical engineering degree from ENSAM and a master of science from Ecole Polytechnique of Montreal.

Sehnaz Ogut

Eastern Europe, Middle East, Africa and Russia (EMEAR)

Sehnaz joined GCA in 2016, leading commercial management of Europe, Middle East, Africa and Russia regions. She has led global roles both in multinational and privately-owned healthcare companies prior to joining GCA and has a strong background in global marketing management and business development.

Bernardo Garduno


Bernardo has 19 years’ experience in the Pharmaceutical and Medical Device industry across Latin America, Asia Pacific and Europe.  His tenure at GCA dates to October 2012 leading accelerated growth strategies in Mexico, Brazil and other Latin American countries.  He has broad experience in commercial operations, strategic marketing, business development and multichannel sales experience.

Marcelo Morkoski

Brazil (BR)

With over 20 years of professional experience developed in the Pharmaceutical and Medical Devices industries of well-known companies. Marcelo joined GCA in 2018 , leading the Brazilian subsidiary.

Federico Stivala

Head of South LATAM

Federico has 14 years´ of successful experience in the pharmaceutical and medical device industry.

He joined GCA in April 2014 as a Marketing Manager and became naturally end of 2015  the Head of South LATAM developing GCA presence and partnership with key players in the industry.

Federico has been a fundamental pillar in the creation of GCA academy which has been then deployed broadly across the group.

Board of Directors

Daniel K. Turner III


Daniel K. Turner III has been Board member and Chairman since October 2010. As managing director and a general partner at Montreux Equity Partners, a private investment company he founded in 1993. Also, currently serving as board directors of moksha8 Pharmaceuticals Inc and multiple companies, including Epirus Biopharmaceuticals, Inc., Glaukos Corporation, Orexigen Therapeutics, Inc., Renal CarePartners, Inc., Transcept Pharmaceuticals, Inc. and Tobira Therapeutics, Inc. Mr. Turner holds a bachelor’s degree from California State University, Sacramento.

William McCabe


William McCabe has been a member of the Board since May 2008. Mr. McCabe is the executive chairman of Oyster Capital Partners, a private investment company he founded in September 2000. Mr. McCabe is also the chief executive officer of Novaerus Limited, a position he has held since September 2013. Mr. McCabe currently serves on the board of directors of Fieldaware Group Limited, Novaerus Group Limited, Novaerus UK Limited and Oyster Technologies Limited and has served on the boards of directors of Datahug Limited and Fleetmatics Group Limited. Mr. McCabe holds a bachelor’s degree from Queens University of Belfast.

Michel Rouif


Has been a member of the Board since April 2015. Dr. Rouif is an aesthetic plastic surgeon in France and has been in private practice since 1994. Dr. Rouif is also a professor at François Rabelais University in Tours and Reneé Descartes University, in Paris, France. Dr. Rouif is Board Certified in France in Plastic, Reconstructive and Aesthetic Surgery and Microsurgery, and has a Diploma of Legal Compensation of Bodily Injuries. Dr. Rouif received a medical degree from René Descartes University, in Paris, France.

Carlos Reis Pinto


Carlos Reis Pinto has been a member of the Board since august 2018. Mr. Reis Pinto is the Chief Executive Officer of GC Aesthetics since September 2017.
Before joining GC Aesthetics Mr. Reis Pinto has been Chief Operations Officer and executive member of 2 private Equity firms on the laboratory testing industry where he structured, developed and succeed 2 outstanding exits. Mr. Reis Pinto holds a master in business from University Paris Sud.

Mariano García-Valiño


Mr. Mariano García-Valiño has been appointed to the Company’s Board of Directors in January 2019. Mr. García-Valiño has been active at the intersection of healthcare, strategy and entrepreneurship for over 25 years. Most recently, Mr. García-Valiño was CEO of GBT (B3:GBIO33), a biopharmaceutical player with presence in ten markets, which he architected, launched and took public in 2017. Mr. Garcia-Valiño holds an Engineering degree from Universidad de Buenos Aires and an MBA from the Harvard Business School.